PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-245.34%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-249.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-146.74%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-145.19%
Negative EPS growth while CRVO is at 100.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-145.19%
Negative diluted EPS growth while CRVO is at 100.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.81%
OCF growth above 1.5x CRVO's 14.10%. David Dodd would confirm a clear edge in underlying cash generation.
39.81%
FCF growth above 1.5x CRVO's 14.43%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.38%
OCF/share CAGR of 21.38% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
21.38%
OCF/share CAGR of 21.38% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
21.38%
3Y OCF/share CAGR of 21.38% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-13.41%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-13.41%
Negative 5Y net income/share CAGR while CRVO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-13.41%
Negative 3Y CAGR while CRVO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-423.21%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-423.21%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-423.21%
Negative 3Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-10.94%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
4.78%
We have some new debt while CRVO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
231.81%
SG&A growth well above CRVO's 11.84%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.